Skip to main content
SpringerLink
Log in

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

  • Chapter
Prognostic variables in node-negative and node-positive breast cancer

  • 134 Accesses

Abstract

The identification of patients at high risk of relapse is currently one of the most important issues in breast cancer research. However, the selection of high-risk patients continues to be difficult due to the unpredictable course of this disease. Axillary lymph node status is currently recognized as the best clinical discriminant between good and poor prognosis, yet almost 30% of node-negative patients and 65% of node-positive patients will experience a relapse. Additional prognostic markers are therefore urgently needed. Since metastatic disease is the main cause of cancer patient morbidity and mortality, the measurement of molecules functionally involved in the regulation of tumor invasion and metastasis is attractive as a means to predict prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pedersen AN, Hoyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW: The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELIS A. J Immun Methods 203:55–65, 1997

    Article  CAS  Google Scholar 

  2. Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG, Kramer MD: Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55:1423–1427, 1995

    PubMed  CAS  Google Scholar 

  3. Dano K, Behrendt N, Brünner N, Ellis V, Plough M, Pyke C: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8:204–215, 1994

    Article  Google Scholar 

  4. Hoyer-Hansen G, Rønne E, Solberg H, Behrendt N, Plough M, Lund LR, et al: Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 267:18224–18229, 1992

    PubMed  CAS  Google Scholar 

  5. Solberg H, Rømer J, Brünner N, Holm A, Sidenius N, Danø K, Høyer-Hansen G: A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 58:877–881, 1994

    Article  PubMed  CAS  Google Scholar 

  6. Grøndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Brünner N, Foekens JA: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1:1079–1087, 1995

    PubMed  Google Scholar 

  7. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJAG, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brünner N: ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868–1876, 1997

    PubMed  CAS  Google Scholar 

  8. Pedersen N, Schmitt M, R0nne E, Nicoletti MI, Hoyer-Hansen G, Conese M, et al: A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 92:2160–2167, 1993

    Article  PubMed  CAS  Google Scholar 

  9. Duffy MJ, O’Grady P, Devaney D, O’Siorain L, Fennelly JJ, Lijnen HR: Tissue type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48:1348–1349, 1988

    PubMed  CAS  Google Scholar 

  10. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4:69–78, 1990

    Google Scholar 

  11. Jänicke F, Schmitt M, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet ii(8670):1049, 1989

    Article  Google Scholar 

  12. Jänicke F, Schmitt M, Graeff H: Both uPA and PAI-1 are independent prognosticators of relapse and death in breast cancer. In: Glas-Greenwalt P (ed) Fibrinolysis in Disease. CRC Press, Boca Raton, pp 19–25

    Google Scholar 

  13. Romain S, Spyratos F, Laine-Bidron C, Bouchet C, Guirou O, Martin PM, Oglobine J, Magdelenat H: Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues. Eur J Clin Chem Clin Biochem 33:603–608, 1995

    PubMed  CAS  Google Scholar 

  14. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor type 1. Cancer Res 54:2527–2530, 1994

    PubMed  Google Scholar 

  15. Bouchet Bernet C, Spyratos F, Andrieu C, Deytieux S, Becette V, Oglobine J: Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues. Breast Cancer Res Treat 41:141–146, 1996

    Article  Google Scholar 

  16. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195–208, 1993

    Article  PubMed  Google Scholar 

  17. Benraad TJ, Geurts-Moespot J, Grondahl-Hansen J, Schmitt M, Heuvel JJTM, de Witte JH, Foekens JA, Leake RE, Brünner N, Sweep CGJ: Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop. Eur J Cancer 32A:1371–1381, 1996

    Article  PubMed  CAS  Google Scholar 

  18. Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F, Benraad T: A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 12:6–14, 1997

    PubMed  CAS  Google Scholar 

  19. Grøndahl-Hansen J, Agerlin N, Munkholm-Larsen P, Nielsen LS, Dombernowsky P, Danø K: Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 111:42–51, 1988

    PubMed  Google Scholar 

  20. Heinert G, Kirchheimer JC, Christ G, Pfluger H, Binder BR: Plasma urokinase-type plasminogen activator correlates to bone scintigraphy in prostate cancer. Eur Urol 15:256–258, 1988

    Google Scholar 

  21. Koelbl H, Kirchheimer JC, Tatra G, Christ G, Binder BR: Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Obstet Gynecol 72:252–256, 1988

    PubMed  CAS  Google Scholar 

  22. Saito K, Nagashima M, Iwata M, Hamada H, Sumi-yoshi K, Takada Y, Takada A: The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thromb Res 58:355–366, 1990

    Article  PubMed  CAS  Google Scholar 

  23. Leung KC, Tung Y, Ali M, Lau WN: Measurement of urokinase-type plasminogen activator activity in sera of nasopharyngeal carcinoma patients by an immunocapture assay. Cancer Lett 58:233–240, 1991

    Article  PubMed  CAS  Google Scholar 

  24. Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR: Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res 53:1788–1793, 1993

    PubMed  CAS  Google Scholar 

  25. von Tempelhoff GF, Heilmann L, Dietrich M, Schneider D, Niemann F, Hommel G: Plasmatic plasminogen activator inhibitor activity in patients with primary breast cancer. Thrombosis and Haemostasis 77:606–608, 1997

    Google Scholar 

  26. Nielsen HJ, Pappot H, Christensen IJ, Brünner N, Thorlacius-Ussing O, Moesgaard F, Danø K, Grøndahl-Hansen J: Association between plasma PAI-1 and survival in patients with colorectal cancer. Br Med J, in press

    Google Scholar 

  27. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Danø K, Brünner N: Identification of high-risk patients in early-stage colorectal cancer by measurement of plasma urokinase receptor. Submitted

    Google Scholar 

  28. Gray RJ: Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87:942–951, 1992

    Article  Google Scholar 

  29. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F, Graeff H: Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 76:306–311, 1997

    Article  PubMed  CAS  Google Scholar 

  30. Duffy MJ, Reilly D, O’Sullivan C, O’Higgins N, Fennelly JJ, Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827–6829, 1990

    PubMed  CAS  Google Scholar 

  31. Bouchet C, Spyratos F, Martin P M, Hacene K, Gentile A, Oglobine J: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69:398–405, 1994

    Article  PubMed  CAS  Google Scholar 

  32. Foekens JA, Schmitt M, van P W, Peters HA, Bonten-bal M, Janicke F, Klijn JG: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101–6105, 1992

    PubMed  CAS  Google Scholar 

  33. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513–2521, 1993

    PubMed  CAS  Google Scholar 

  34. Grondahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N: Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clinical Cancer Res 3:233–239, 1997

    CAS  Google Scholar 

  35. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195–208, 1993

    Article  PubMed  Google Scholar 

  36. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Le DV, Tubiana-Hulin M, Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266–1272, 1992

    Article  PubMed  CAS  Google Scholar 

  37. Fernö M, Bendahl P-O, Borg Å, Brundell J, Hirsch-berg L, Olsson H, Killander D: Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A:793–801, 1996

    Article  PubMed  Google Scholar 

  38. Jänicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostasis 17:303–312, 1991

    Article  Google Scholar 

  39. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Janicke F, Klijn JG: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648–1658, 1994

    PubMed  CAS  Google Scholar 

  40. Duggan C, Maguire T, McDermott E, O’Higgins N, Fennelly JJ, Duffy MJ: Urokinase plasminogea activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61:597–600, 1995

    Article  PubMed  CAS  Google Scholar 

  41. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S: Plasminogen activator system in human breast cancer. Int J Cancer 50:345–348, 1992

    Article  PubMed  CAS  Google Scholar 

  42. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG: Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87:751–756, 1995

    Article  PubMed  CAS  Google Scholar 

  43. Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Graeff H, Schmitt M: Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Research 1998, in press

    Google Scholar 

  44. Clark GM: Integrating prognostic factors. Breast Cancer Res Treat 22:187–191, 1992

    Article  PubMed  CAS  Google Scholar 

  45. Sweep CGJ, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJTM, Schmitt M, Duffy MJ, Jänicke F, Kramer MD, Foekens JA, Brünner N, Brugal G, Pedersen AN, Benraad TJ: External quality assessment of trans-European multicentre antigen determinations (ELISA) of urokinase-type plasmin-ogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts. British J Cancer, in press

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Finsen Laboratory, Copenhagen, Denmark

    Ross W. Stephens & Nils Brünner

  2. Finsen Laboratory, Strandboulevarden 49, DK-2100, Copenhagen, Denmark

    Ross W. Stephens

  3. Frauenklinik der Universität Hamburg, Universitäts-Krankenhaus Eppendorf, Hamburg, Germany

    Fritz Jänicke

  4. Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, Münich, Germany

    Manfred Schmitt

Authors
  1. Ross W. Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nils Brünner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fritz Jänicke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manfred Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Giampietro Gasparini

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Stephens, R.W., Brünner, N., Jänicke, F., Schmitt, M. (1998). The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. In: Gasparini, G. (eds) Prognostic variables in node-negative and node-positive breast cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5195-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5195-9_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7366-7

  • Online ISBN: 978-1-4615-5195-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation